Designing immunotherapies to thwart drug abuse

Molecular Interventions

Volumn 9, Issue 3, 2009, Pages 119-124

  Peterson, Eric C ^a   Owens, S Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; COCAINE; COCAINE VACCINE; IMMUNOGLOBULIN G ANTIBODY; METHAMPHETAMINE; METHAMPHETAMINE VACCINE; MONOCLONAL ANTIBODY; NICOTINE; NICOTINE VACCINE; PHENCYCLIDINE; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ADDICTION; ANTIBODY SPECIFICITY; BEHAVIOR THERAPY; BINDING AFFINITY; CLINICAL TRIAL; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DEPENDENCE; DRUG EFFECT; DRUG HALF LIFE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LOCOMOTION; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW;

ANIMALS; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; SUBSTANCE-RELATED DISORDERS;

EID: 67650457646     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.3.5     Document Type: Review

References (47)

1. Nicosia, N., Pacula, R.L., Kilmer, B., Lundberg, R., and Chiesa, J. The Economic Cost of Methamphetamine Use in the United States, 2005. Drug Policy Research Center. RAND Corporation Monograph Series. www.rand.org/pubs/ monographs/2009/RAND-MG829.pdf
2. Richards, J.R., Bretz, S.W., Johnson, E.B., Turnipseed, S.D., Brofeldt, B.T., and Derlet, R.W. Methamphetamine abuse and emergency department utilization. West. J. Med. 170, 198-202 (1999).
3. Sato, M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann. N.Y. Acad. Sci. 654, 160-170 (1992).
4. Albertson, T.E., Derlet, R.W., and Van Hoozen, B.E. Methamphetamine and the expanding complications of amphetamines. West. J. Med. 170, 214-219 (1999).
5. Proksch, J.W., Gentry, W.B., and Owens, S.M. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J. Pharmacol. Exp. Ther. 292, 831-837 (2000). The results in this article demonstrate the ability of a very high affinity antibody reduce brain drug concentrations for at least 27 days in rats.
6. Pentel, P.R., Malin, D.H. , Ennifar, S. et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65, 191-198 (2000).
7. Fox, B.S. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend. 48, 153-158 (1997).
8. Byrnes-Blake, K.A., Laurenzana, E.M., Landes, R.D., Gentry, W.B., and Owens, S.M. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur. J. Pharmacol. 521, 86-94 (2005).
9. Holliger, P. and Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotech. 23, 1126-1136 (2005). An excellent review of the many antibody fragment forms that have been engineered and the relative advantages of each one.
10. Bonese, K.F., Wainer, B.H., Fitch, F.W., Rothberg, R.M., and Schuster, C.R.. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252, 708-710 (1974). This is a seminal article in the field of active immunization, showing that immunization with a drug-like hapten can alter a primate's response to an addictive drug.
11. Hieda, Y., Keyler, D.E., Vandevoort, J.T., Kane, J.K., Ross, C.A., Raphael, D.E., Niedbalas, R.S., and Pentel, P.R. Active immunization alters the plasma nicotine concentration in rats. J. Pharmacol. Exp. Ther. 283, 1076-1081 (1997).
12. Keyler, D.E., Hieda, Y., St. Peter, J., and Pentel, P.R. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob. Re.s 1, 241-249 (1999).
13. Hieda, Y., Keyler, D.E., VanDeVoort, J.T., Niedbala, R.S., Raphael, D.E., Ross, C.A., and Pentel, P.R. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl) 143, 150-157 (1999).
14. Hieda, Y., Keyler, D.E., Ennifar, S., Fattom, A., and Pentel, P.R. Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol. 22, 809-819 (2000).
15. de Villiers, S.H., Lindblom, N., Kalayanov, G., Gordon, S., Malmerfelt, A., Johansson, A.M., and Svensson, T.H. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 69, 247-253 (2002).
16. Lindblom, N., de Villiers, S.H., Kalayanov, G., Gordon, S., Johansson, A.M., and Svensson, T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 69, 254-260 (2002).
17. Fox, B.S., Kantak, K.M., Edwards, M.A. et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 2, 1129-1132 (1996).
18. Kantak, K.M., Collins, S.L., Lipman, E.G., Bond, J., Giovanoni, K., and Fox, B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 148, 251-262 (2000).
19. Carrera, M.R., Ashley, J.A., Zhou, B., Wirsching, P., Koob, G.F., and Janda, K.D. Cocaine vaccines: Antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. U.S.A. 97, 6202-6206 (2000).
20. Carrera, M.R., Ashley, J.A., Wirsching, P., Koob, G.F., and Janda, K.D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci. U.S.A. 98, 1988-1992 (2001).
21. Byrnes-Blake, K.A., Carroll, F.I., Abraham, P., and Owens, S.M. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int. Immunopharmacol. 1, 329-338 (2001). This article reports that concurrent use of methamphetamine does not reduce the immune response to an anti-METH vaccine. This is an important finding, since many addicts seeking treatment will likely continue to use drug at some level while waiting for anti-drug antibody titers to develop in their bodies.
22. Kosten, T. and Owens, S.M. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther. 108, 76-85 (2005).
23. Gentry, W.B., Ruedi-Bettschen, D., and Owens, S.M. Development of active and passive human vaccines to treat methamphetamine addiction. Hum. Vaccin. Apr 20; 5(4). [Epub ahead of print] (2009).
24. Cornuz, J., Klingler, K., Mueller, P., Jungi, F., and Cerny, T. A therapeutic vaccine for nicotine dependence: Results of a phase I and a randomized phase II study. J. Clin. Oncol. 23, 1008 (2005).
25. St. Clair Roberts, J., Dobson, J., Wood, D., and , Settles, M. Safety and Immunogenicity of a Human Nicotine Conjugate Vaccine. In College on Problems of Drug Dependence Annual Meeting, Quebec City, Canada (2002).
26. Kosten, T.R., Rosen, M., Bond, J., Settles, M., Roberts, J.S., Shields, J., Jack, L., and Fox, B. Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 20, 1196-1204 (2002).
27. Martell, B.A., Mitchell, E., Poling, J., Gonsai, K., and Kosten, T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry 58, 158-164 (2005).
28. Duryee, M.J., Bevins, R.A., Reichel, C.M., Murray, J.E., Dong, Y., Thiele, G.M., and Sanderson, S.D. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 27, 2981-2988 (2009).
29. Taylor, S.M., Sherman, S.A., Kirnarsky, L., and Sanderson, S.D. Development of response-selective agonists of human C5a anaphylatoxin: Conformational, biological, and therapeutic considerations. Curr. Med. Chem. 8, 675-684 (2001).
30. Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357 (2006). An excellent review in the area of translational immunology. The author presents a thorough discussion of antibody characteristics that are important to consider when developing antibodies as therapeutics.
31. Laurenzana, E.M., Byrnes-Blake, K.A., Milesi-Halle, A., Gentry, W.B., Williams, D.K., and Owens, S.M. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab. Dispos. 31, 1320-1326 (2003).
32. Gentry, W.B., Laurenzana, E.M., Williams, D.K., West, J.R., Berg, R.J., Terlea, T., and Owens, S.M. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int. Immunopharmacol. 6, 968-977 (2006).
33. Byrnes-Blake, K.A., Laurenzana, E.M., Carroll, F.I., Abraham, P. Gentry, W.B., Landes, R.D., and Owens, S.M. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur. J. Pharmacol. 461, 119-128 (2003).
34. McMillan, D.E., Hardwick, W.C., Li, M., Gunnell, M.G., Carroll, F.I., Abraham, P., and Owens, S.M. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J. Pharmacol. Exp. Ther. 309, 1248-1255 (2004).
35. Lobo, E.D., Hansen, R.J., and Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645-2668 (2004).
36. Roskos, L.K., Davis, C.G., and Schwab, G.M. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res. 61, 108-120 (2004).
37. Ghetie, V. and Ward, E.S. Transcytosis and catabolism of antibody. Immunol. Re.s 25, 97-113 (2002). This review article summarizes the role of the FcRn receptor and its effect on antibody pharmacokinetics. Importantly, it also addresses the transfer of IgG across the plecental barrier during pregnancy, important to consider when developing antibodies that could protect the fetus from the effects of drug abuse.
38. Trang, J. Pharmacokinetics and Metabolism of Therapeutic and Diagnostic Antibodies. In, Protein Pharmacokinetics and Metabolism. B. Ferraiolo, M. Mohler, and C. Gloff, eds. Plenum Press, New York. 223-270 (1992).
39. Goel, A., Colcher, D., Baranowska-Kortylewicz, J., Augustine, S., Booth, B.J., Pavlinkova, G., and Batra, S.K. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application. Cancer Res. 60, 6964-6971 (2000).
40. Peterson, E.C., Laurenzana, E.M., Atchley, W.T., Hendrickson, H.P., and Owens, S.M. Development and preclinical testing of a high-affinity singlechain antibody against (+)-methamphetamine. J. Pharmacol. Exp. Ther. 325, 124-133 (2008).
41. Shelver, W.L., Keyler, D.E., Lin, G., Murtaugh, M.P., Flickinger, M.C., Ross, C.A., and Pentel, P.R. Effects of recombinant drug-specific single chain antibody Fv fragment on [3H]-desipramine distribution in rats. Biochem. Pharmacol. 51, 531-537 (1996). The authors in this article present early research on using antibody fragments to treat drug overdose and the ability of scFvs to alter drug disposition.
42. Lee, L.S., Conover, C., Shi, C., Whitlow, M., and Filpula, D. 1999. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds. Bioconjug. Chem. 10, 973-981 (1999).
43. Hudson, P.J. and C. Souriau, C. Engineered antibodies. Nat. Med. 9, 129-134 (2003).
44. Dolezal, O., Pearce, L.A. Lawrence, L.J., McCoy, A.J., Hudson, P.J., and Kortt, A.A. ScFv multimers of the anti-neuraminidase antibody NC10: Shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng. 13, 565-574 (2000).
45. Boas, U. and Heegaard, P.M. Dendrimers in drug research. Chem. Soc. Rev. 33, 43-63 (2004).
46. Kukowska-Latallo, J.F., Candido, K.A., Cao, Z., Nigavekar, S.S., Majoros, I.J., Thomas, T.P., Balogh, L.P., Khan, M.K., and Baker, J.R., Jr. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65, 5317-5324 (2005). The results of this article demonstrate that dendrimers can be used as carriers of many functional chemicals simultaneously, thereby creating a single molecule that has increased efficacy over the individual components.
47. Peterson, E., S. M. Owens, and R. L. Henry. Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse. AAPS J. 8, E383-E390 (2006).